Abstract
The purpose of this paper is to identify a selection of key business models - “typology” - applied in the biotechnology industry. The focus is on the differences between traditional/closed or stand-alone business models opposed to open or networked business models. A number of illustrative case studies and good practices are presented to show that new biotechnology firms are gradually adopting a “best of both worlds” strategy, with both closed business models and open, networked models as a way for gaining access to the market, in close collaboration with large global pharmaceutical companies. The case firms and good practices are taken from a recent country study for Belgium.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
